Skip to main content
. 2018 Apr 25;105(10):1338–1348. doi: 10.1002/bjs.10871

Figure 4.

BJS-10871-FIG-0004-c

a Forest plot showing the survival impact of immunoscore stratified by type of adjuvant chemotherapy (CT) among patients with stage II and III gastric cancer. Hazard ratios, with 95 per cent confidence intervals, are shown for the high immunoscore group versus the low immunoscore group. b Forest plot showing the benefit of CT in different immunoscore groups of patients with stage II and III gastric cancer. Hazard ratios, with 95 per cent confidence intervals, are shown for CT versus no CT in each immunoscore group. XP, xeloda plus cisplatin; LF, leucovorin plus fluorouracil